| 1161/1816 | US=58 / Câncer Post SM, Quinás-Cardama A, Lozano G. Regulation of p53 activity and associated checkpoint controls. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 171-88. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. P53; MDM2; P19; TUMORIGENESE; CANCER; RAS; CICLO CELULAR; RB; CICLINA; CDK |
| 1162/1816 | US=58 / Câncer Eastman A. The importance of p53 signaling in the response of cells to checkpoint inhibitors. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 189-98. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. DANOS NO DNA; PARADA DO CICLO CELULAR; P53; P21; CICLINA B; CHK1 INIBIDORES; UCN-01; INIBIDORES DA TOPOISOMERASE II; ANALOGOS DE NUCLEOSIDOS |
| 1163/1816 | US=58 / Câncer Siddik ZH. Targeting p21-dependent pathways for cell death in cancer therapy. In: ___. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 199-213. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. DANOS NO DNA; P21; CICLINA DEPENDENTE DE QUINASE; G1 RESPOSTA CHECKPOINT; PARADA DO CICLO CELULAR; TRANSATIVACAO; PARADA DO CICLO GENE |
| 1164/1816 | US=58 / Câncer Le XF, Bast Junior RC. p27Kip1 as a biomark and target for treatment of cancer. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 215-33. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. P27KIP1; CICLO CELULAR; SUPRESSOR DE TUMOR; TERAPIA ALVO; TRASTUZUMAB |
| 1165/1816 | US=58 / Câncer Pevarello P, Bischoff JR, Mercurio C. Targeting cyclin-dependent kinases with small molecular inhibitors. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 235-44. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CICLINA DEPENDENTE DE QUINASE; INIBIDOR DE MOLECULA PEQUENA; SELETIVIDADE; DE MULTI-ALVO; ENSAIOS CLINICOS |
| 1166/1816 | US=58 / Câncer Zhang H, Xiao Z, Sowin T. ChK1 and ChK2 as checkpoint targets. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 245-59. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CHK1; CHK2; INIBIDORES; PARADA DO CICLO CELULAR; REVOGACAO DA RESPOSTA CHECKPOINT; CHEMOPROTECTION; BIOMARCADORES PREDITIVOS |
| 1167/1816 | US=58 / Câncer Rudolph J. Targeting Cdc25 phosphatases in cancer therapy. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 261-9. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CDC25 FOSFATASE; CICLO CELULAR; CANCER; AGENTES ANTI-PROLIFERATIVOS |
| 1168/1816 | US=7 / Farmacologia Wells BG, DiPiro JT, Schwinghammer TL, DiPiro Cecily V. Human immunodeficiency virus/acquired immune deficiency syndrome. In: ___. Pharmacotherapy handbook. 7th ed. New York: McGraw-Hill, 2008. p. 435-49. ISBN 978-0-07-148501-2. VIRUS DA IMUNODEFICIENCIA HUMANA; SINDROMA DE IMUNODEFICIENCIA ADQUIRIDA; VIRUS DA IMUNODEFICIENCIA HUMANA. TRANSMISSAO |
| 1169/1816 | US=80 / Biol/Mol Willard B, Kaveti S, Kinter MT. Proteomics technologies: current and emergig mass spectrometry instrumentation and methods for proteomic analyses. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 3-35. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7. ESPECTROMETRIA DE MASSA; ION FRAGMENTACAO; PROTEOMICA; ANALISE DE MASSA |
| 1170/1816 | US=80 / Biol/Mol Lee K, Wang T, Rehman A, Wang Y, Daoud SS. Cell signaling proteomics: integration of genomics and proteomics in dissecting p53 signaling. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 39-57. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7. FARMACOGENOMICA; PROTEOMICA; P53; S100A4; RB18A; CANCER DO COLON |
| 1171/1816 | US=80 / Biol/Mol Alaoui-Jamali MA, Pinto D. Proteomic profiling of tyrosine kinases as pharmacological endpoints for targeted cancer therapy. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 59-77. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7. TIROSINA-QUINASES PROTEICAS; CANCER; TERAPIA-ALVO; PROTEOMICA |
| 1172/1816 | US=80 / Biol/Mol Jain KK. Tumor proteomics: oncoproteomics for personalized management of cancer. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 81-99. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7. MICROARRAYS DE PROTEINA; DROGAS ANTICANCER; BIOMARKETING; CANCER; ONCOPROTEOMICS; MEDICINA PERSONALIZADA; FARMACOGENOMICA; PHARMACOPROTEOMICS; PERFIL DE PROTEINAS; PROTEOMICA |
| 1173/1816 | US=80 / Biol/Mol Annunziata CM, Roque DM, Azad N, Kohn EC. Application of serum and tissue proteomics to understand and detect solid tumors. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 101-20. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7. PROTEOMICA; ENSAIO CLINICO; TUMOR SOLIDO; ESPECTROMETRIA DE MASSA; TISSUE MICROARRAY |
| 1174/1816 | US=80 / Biol/Mol Sarto C, Proserpio V, Magni F, Mocarelli P. Insight on renal cell carcinoma proteome. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 121-37. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7. CARCINOMA DE CELULAS RENAIS PROTEOMA; CARCINOMA DE CELULAS RENAIS; PROTEOMA; GENOMICA; BIOMARCADORES; ELECTROFORESE BIDIMENSIONAL; ANALISE SEROLOGICA PROTEOMA; MODIFICACAO POS-TRADUCAO |
| 1175/1816 | US=80 / Biol/Mol Reumond MA, Beshay M, Lippert H. Proteomics in lung cancer. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 139-59. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7. PROTEOMICA NO CANCER DE PULMAO; CANCER DE PULMAO; PROTEOMICA; HNRNP; CITOQUERATINAS; LCM |
| 1176/1816 | US=80 / Biol/Mol Gjertsen BT, Sjoholt G. Proteomic strategies of therapeutic individualization and target discovery in acute myeloid leukemia. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 161-87. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7. LEUCEMIA MIELOIDE AGUDA; BIOMARCADORES; PHARMACOPROTEOMICS; ACIDO TRANS-RETINOICO; INIBIDORES DE QUINASE DE TIROSINA; HISTONA DEACETILASE INIBIDORES; INIBIDORES DE PROTEASSOMA |
| 1177/1816 | US=80 / Biol/Mol Brünner N, Holten-Andersen M, Sweep F, Foekens J, Schmitt M, Duffy MJ. New tumor biomarkers. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 189-207. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7. BIOMARCADORES TUMORAIS; PRE-ANALITICA VARIAVEIS; VARIAVEL ANALITICA; POS-ANALITICA VARIAVEL; MARCADORES DE DETECCAO DE MARCADORES DE TRIAGEM; MARCADORES PROGNOSTICOS; MARCADORES PREDITIVOS; MARCADORES DE MONITORAMENTO |
| 1178/1816 | US=80 / Biol/Mol Apweiler R, Mueller M. Bioinformatics and regulatory aspects of proteomics: annotating the human proteome. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 211-35. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7. HUMANO; PROTEOMICA; ANOTACAO FUNCIONAL; INTEGRACAO DE DADOS; PADRONIZACAO DE DADOS |
| 1179/1816 | US=80 / Biol/Mol Li D, Hackett J, Chan M, Pennello G, Gutman S. Regulatory issues in the co-development of oncology drugs and proteomic tests: an overview. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 237-58. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7. |
| 1180/1816 | US=64 / Câncer Dhodapkar MV. Immunobiology and immunotherapy of multiple myeloma. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 167-202. (Comtemporary Hematology) ISBN 978-1-934115-82-4. IMUNOLOBIOLOGIA DO MIELOMA MULTIPLO; IMUNOTERAPIA DO MIELOMA MULTIPLO |